Funded Biotechnology Startups in San Mateo
Among the 12 most recent biotechnology rounds shown for San Mateo, the largest disclosed amount is Sagimet Biosciences at $175M on 2026-04-27, which dwarfs…
Among the 12 most recent biotechnology rounds shown for San Mateo, the largest disclosed amount is Sagimet Biosciences at $175M on 2026-04-27, which dwarfs the next-highest disclosed rounds (Terns Pharmaceuticals at $87M on 2021-01-05 and Helicore Biopharma at $65M on 2025-01-28). Most disclosed amounts cluster well below $100M: only Terns ($87M), Helicore ($65M), and Vivace Therapeutics ($35M) and Tranquis ($30M) sit in the higher end versus the several smaller disclosed rounds such as Selonterra at $3M (2024-10-08).
The list also shows two temporal clusters, with four rounds in the most recent window (2025-03-12 through 2026-04-02, including Vivace’s $35M on 2025-03-12 and Rakuten Medical’s undisclosed round on 2026-04-02) and another run earlier in the decade (2020-07-09 through 2022-08-11). Stage/disclosure patterns are mixed: “Series Unknown” appears on multiple entries (Selonterra 2024-10-08, Sagimet 2026-04-27, Rakuten Medical 2026-04-02, and PrognomiQ 2022-03-15), while two rows list “undisclosed” amounts (Rakuten Medical 2026-04-02 and Revagenix 2024-01-05).
Most recent rounds
12 shownRelated listings
Frequently asked
What does the top disclosed round look like compared with the rest of the San Mateo biotechnology rounds shown?
Sagimet Biosciences’ $175M round on 2026-04-27 is a clear outlier; the next-largest disclosed amounts are Terns Pharmaceuticals at $87M (2021-01-05) and Helicore Biopharma at $65M (2025-01-28), leaving most other disclosed rounds clustered below $50M.
Are there noticeable date windows where multiple rounds closed in this list?
Yes. Four rounds fall in a recent cluster from 2025-03-12 to 2026-04-02 (Vivace Therapeutics $35M on 2025-03-12; Helicore Biopharma $65M on 2025-01-28; Sagimet Biosciences $175M on 2026-04-27; Rakuten Medical undisclosed on 2026-04-02), while another multi-year run spans 2021-04-22 through 2022-08-11 (Edifice Health $12M in 2021, Terns $87M in 2021, Levita Magnetics $26M in 2022, and PrognomiQ $46M in 2022).
How often are the rounds disclosed versus undisclosed in this specific set of 12 rows?
Two entries show “undisclosed” amounts: Rakuten Medical on 2026-04-02 and Revagenix on 2024-01-05. Separately, several entries use “Series Unknown” (Sagimet Biosciences 2026-04-27 at $175M; Rakuten Medical 2026-04-02 undisclosed; Selonterra 2024-10-08 at $3M; PrognomiQ 2022-03-15 at $46M), which limits stage comparability even when an amount is shown.
Which stage labels appear repeatedly, and does that pattern align with the larger or smaller disclosed amounts?
“Series Unknown” shows up on four companies (Sagimet Biosciences $175M on 2026-04-27; Rakuten Medical undisclosed on 2026-04-02; Selonterra $3M on 2024-10-08; PrognomiQ $46M on 2022-03-15), spanning both the largest disclosed round and the smallest disclosed amount. By contrast, labeled Series rounds like Series A (Helicore $65M on 2025-01-28) and Series C (Terns $87M on 2021-01-05) include some of the higher disclosed figures but are not as frequent.
Is there a clear low-end outlier among disclosed amounts?
Selonterra’s $3M on 2024-10-08 is the smallest disclosed amount in the shown rows. It sits far below other lower disclosed rounds like Edifice Health $12M (2021-04-22) and Revagenix (undisclosed) on 2024-01-05, making it the most prominent disclosed “floor” in this set.
What stage mix is visible among the most recent entries in this page’s timeframe?
In the most recent entries (2025-03-12, 2025-01-28, 2026-04-02, 2026-04-27), the stage/disclosure labels are mixed: Vivace Therapeutics is explicitly Series D with $35M (2025-03-12), Helicore Biopharma is Series A with $65M (2025-01-28), while Sagimet Biosciences is “Series Unknown” at $175M (2026-04-27) and Rakuten Medical is “Series Unknown” with an undisclosed amount (2026-04-02).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.